Moore Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Moore Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-125,000	Closed	-$1.26M	–	628
2022 Q4	$1.26M	Hold	125,000	–	–	0.03%	312
2022 Q3	$1.24M	Hold	125,000	–	–	0.03%	398
2022 Q2	$1.22M	Hold	125,000	–	–	0.03%	384
2022 Q1	$1.22M	Hold	125,000	–	–	0.03%	416
2021 Q4	$1.21M	Hold	125,000	–	–	0.02%	446
2021 Q3	$1.21M	Hold	125,000	–	–	0.02%	495
2021 Q2	$1.21M	Buy	+125,000	New	+$1.23M	0.02%	512

Moore Capital Management's EBAC Position: Q1 2023 in Review

Moore Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 125,000 shares — an estimated $1.26M sold.

Moore Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $1.26M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Moore Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Moore Capital Management sold 125,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $1.26M.
Moore Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Moore Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.26M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.